Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 118   

Articles published

JNJ 105.17 +0.45 (0.43%)
price chart
Johnson & Johnson to Quicken Development of Ebola Virus Vaccine
Johnson & Johnson said the vaccine program is being accelerated to allow for clinical trials in humans in early 2015, after promising results in preclinical studies.
Johnson & Johnson Pushes Ahead With Ebola Vaccine  NPR (blog)
Johnson & Johnson (JNJ) to Accelerate Development of Ebola Vaccine  InvestorGuide
Related articles »  
One Put, One Call Option To Know About for Johnson & Johnson
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson Johnson & Johnson (NYSE: JNJ). So this week we highlight one interesting put contract, and one interesting call ...
Related articles »  
Weekly Pharma Notes: Bristol-Myers Squibb, Johnson & Johnson, Merck And ...
Johnson & Johnson recently stated that it is accelerating the development of a vaccine against the Zaire strain of the Ebola Virus that has been responsible for the current outbreak in Africa.
Related articles »  
Is It Time to Buy Johnson & Johnson's Stock?
A common belief among investors is that it can be considerably tougher for megacap blue-chip companies to double compared to small-caps stocks.
Related articles »  
Johnson & Johnson to Seek Buyer for Cordis Medical-Device Unit
The sales process for the business, called Cordis, is at an early stage, the people said. The business, which could fetch between $1.5 billion and $2 billion, is expected to attract interest from private-equity firms and other health-care companies ...
Johnson & Johnson to seek buyer for medical device maker unit: WSJ  Reuters
Johnson & Johnson Plans To Divest Its Cordis Business  Bidness ETC
Related articles »  
Johnson & Johnson vs. Abbott Laboratories in the Battle for Emerging Market Turf
Based on my 8 rules of dividend investing (more on that below), Abbott Laboratories has the advantage, but Johnson & Johnson is a fantastic company as well. Both businesses make excellent investments for long-term oriented shareholders seeking rising ...
Related articles »  
Johnson & Johnson Should Ignore Those Breakup Calls
Still, there are plenty of investors calling for Johnson & Johnson to break itself up into smaller pieces, even though the company is posting 9% year-over-year revenue growth.
Johnson & Johnson: The One Stock You Should Ever Own? (JNJ)  Seeking Alpha (registration)
Short Interest in Johnson & Johnson Decreases By 13.2% (JNJ)  Mideast Time
Related articles »  
Sharper Focus Pays Dividends At Johnson & Johnson
Last week,Johnson & Johnson ( JNJ ) and its partner Bayer announced new studies to evaluate the drug for new indications.
Sharper Focus Pays Dividends At Johnson & Johnson JNJ  Investor's Business Daily
Stock Update (NYSE:JNJ): Johnson & Johnson to Participate in 2014 Morgan ...  Jutia Group
Related articles »  
Johnson & Johnson Seems Expensive Relative To Historical Valuation Metrics ...
However, recall that Johnson & Johnson's expected future earnings growth rate is higher than it has been in the previous several years, so that factor helps explain this elevated valuation.
Related articles »  
Interesting January 2015 Stock Options for Johnson & Johnson
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson JNJ +0.13% (NYSE: JNJ). So this week we highlight one interesting put contract, and one interesting call contract ...
Related articles »